Alzheimer's Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Alzheimer's Disease stocks.

Alzheimer's Disease Stocks Recent News

Date Stock Title
May 31 PFE Pfizer Reports Encouraging Long-Term Trial Results of Advanced Lung Cancer Drug
May 31 PFE The Most Profitable Biotechnology Company in the World
May 31 PFE Moderna Looks for Boost From Newly Approved RSV Shot
May 31 PFE Moderna Wins FDA Approval For Second-Ever Product; Why Its RSV Vaccine Could Dominate Pfizer, GSK
May 31 PFE Pfizer (PFE) Up 1.8% Since Last Earnings Report: Can It Continue?
May 31 OPK OPKO Health to Participate in the Jefferies Global Healthcare Conference
May 31 PFE Pfizer posts long-term data to support lung cancer therapy Lorbrena
May 31 PFE Pfizer gene therapy for haemophilia B therapy endorsed in EU
May 31 PFE Pfizer’s LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression
May 31 SPRC SciSparc Secures Strategic Advantage with Grant of European Patent
May 31 PFE Moderna wins FDA approval for RSV vaccine
May 31 PFE Ginkgo Bioworks Stock: Bull vs. Bear
May 31 PFE Is Pfizer an Excellent Dividend Stock to Buy for Passive Income Investors?
May 30 PFE Pfizer's Options Frenzy: What You Need to Know
May 30 PFE Third human bird flu case found in U.S.
May 30 PFE Moderna Pops After Confirming The U.S. Government Could Back Its Bird Flu Vaccine
May 30 PFE 3 Dividend Stocks to Double Up on Right Now
May 30 PFE Biohaven doses first subject in Phase I/II tumour treatment study
May 29 PFE Roche's (RHHBY) Inavolisib NDA Gets FDA Priority Review Tag
May 29 PRTA Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate
Alzheimer's Disease

Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60–70% of cases of dementia. The most common early symptom is difficulty in remembering recent events (short-term memory loss). As the disease advances, symptoms can include problems with language, disorientation (including easily getting lost), mood swings, loss of motivation, not managing self care, and behavioural issues. As a person's condition declines, they often withdraw from family and society. Gradually, bodily functions are lost, ultimately leading to death. Although the speed of progression can vary, the typical life expectancy following diagnosis is three to nine years.The cause of Alzheimer's disease is poorly understood. About 70% of the risk is believed to be genetic with many genes usually involved. Other risk factors include a history of head injuries, depression, or hypertension. The disease process is associated with plaques and tangles in the brain. A probable diagnosis is based on the history of the illness and cognitive testing with medical imaging and blood tests to rule out other possible causes. Initial symptoms are often mistaken for normal ageing. Examination of brain tissue is needed for a definite diagnosis. Mental and physical exercise, and avoiding obesity may decrease the risk of AD; however, evidence to support these recommendations is not strong. There are no medications or supplements that have been shown to decrease risk.No treatments stop or reverse its progression, though some may temporarily improve symptoms. Affected people increasingly rely on others for assistance, often placing a burden on the caregiver; the pressures can include social, psychological, physical, and economic elements. Exercise programmes may be beneficial with respect to activities of daily living and can potentially improve outcomes. Behavioural problems or psychosis due to dementia are often treated with antipsychotics, but this is not usually recommended, as there is little benefit with an increased risk of early death.In 2015, there were approximately 29.8 million people worldwide with AD. It most often begins in people over 65 years of age, although 4% to 5% of cases are early-onset Alzheimer's which begin before this. It affects about 6% of people 65 years and older. In 2015, dementia resulted in about 1.9 million deaths. It was first described by, and later named after, German psychiatrist and pathologist Alois Alzheimer in 1906. In developed countries, AD is one of the most financially costly diseases.

Browse All Tags